Eli Lilly will file its triple-agonist obesity drug retatrutide in early 2027 via a Biologics License Application, seeking stronger market protections. Positive Phase 3 results showed up to 22.6% weight loss, while cardiovascular safety data raised some questions.
Rhythm Pharmaceuticals announced expanded Phase 3 TRANSCEND trial data showing an 18.8% placebo-adjusted BMI reduction at 52 weeks for setmelanotide in acquired hypothalamic obesity, with FDA PDUFA goal date set for March 20, 2026.
Soleno Therapeutics provided updates on its VYKAT XR commercial launch for Prader-Willi syndrome, reporting reimbursement progress across nearly 48 Medicaid programs and over 600 prescribers, while European regulatory review continues for approximately 9,500 additional patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07590219 |
Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT07280845 |
Longitudinal Retrospective Analysis of Prospectively Collected Data for Outcomes After Primary Sleeve Gastrectomy (N=20 000) in the Swedish National Quality Registry SOReg (Scandinavian Obesity Surgery Registry) |
COMPLETED | |
| NCT07158008 |
Comparison of Nissen-Sleeve and Gastric Bypass for GERD in Obese Patients |
RECRUITING | NA |
| NCT07135141 |
Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity |
NOT_YET_RECRUITING | NA |
| NCT07058155 |
Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease |
RECRUITING | PHASE4 |
| NCT06757296 |
Endoscopic Conversion of Sleeve Gastrectomy to Single Anastomosis Sleeve-ileal Bypass (SASI) for Gastroesophageal Reflux (GERD), Primary and Secondary Non-responder. |
RECRUITING | NA |
| NCT06547515 |
Bone and Muscle Health Following Sleeve Gastrectomy in Men, Premenopausal and Postmenopausal Women |
RECRUITING | |
| NCT06162715 |
GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial |
ACTIVE_NOT_RECRUITING | PHASE2/PHASE3 |
| NCT06162416 |
Non-opioid Anesthesia in Bariatric Surgery |
RECRUITING | |
| NCT06043245 |
Diabetes Remission and Hypoabsorptive Bariatric Surgery |
ENROLLING_BY_INVITATION | NA |
